Tandem Diabetes Care Stock Soars 12.2% to Intraday High of $14.85

Tandem Diabetes Care, Inc. has experienced a significant surge in its stock price, gaining 12.2% on October 3, 2025. The stock reached an intraday high of USD 14.85, marking a notable performance in the Pharmaceuticals & Biotechnology sector. In terms of performance metrics, Tandem Diabetes Care has shown a remarkable 22.58% increase over the past week, significantly outpacing the S&P 500's 1.09% gain during the same period. Over the last month, the stock has risen by 19.11%, while the S&P 500 has only managed a 4.15% increase. However, it is important to note that the stock has faced challenges over the longer term, with a decline of 63.64% over the past year and a staggering 86.75% drop over the last five years. Despite the recent uptick, Tandem Diabetes Care's financial health raises concerns, highlighted by a low return on equity of 0.30% and a high debt-equity ratio of 100.27%. These factors contribute to a complex outlook for the company, which operates within a small-cap market valued at approximately USD 845 million.